Exclusive: U.S. Chamber Lobbies Against China Drug Registration Revisions That Would Favor Local Generics
This article was originally published in PharmAsia News
Executive Summary
The U.S. Chamber of Commerce is lobbying China FDA over its recent draft drug registration regulations, which would allow approval of generics while an originator’s patent is still valid. Big pharma could face faster and stronger generic competition in China if CFDA finalizes the regulations without revision.
You may also be interested in...
China To Implement New Regulations For Patent Law; Companies Should Set Up Inventor Reward Policy To Prepare For Changes
SHANGHAI - China's State Council recently approved new implementation regulations for the country's Patent law, which clarifies procedural issues in line with new changes to the patent law that took effect last year
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.